Loading…
Werewolf Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -93.9% over 5Y.
today you would have $55.94▼ -94.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $0.63 | $1.48 | $3.86 | $2.05 | $11.91 | |
| P/B | 1.2x | 1.2x | 0.9x | 1.5x | 0.6x | 2.2x |
| EPS | -$1.33 | -$1.63 | -$1.05 | -$1.86 | -$10.94 | |
| ROE | -43.99% | -245.20% | -96.08% | -33.55% | -43.99% | -32.71% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CELUCelularity Inc | $1.58 | — | — | — | — | $45.73M |
| LITSLite Strategy, Inc. | $1.36 | — | 0.8x | — | -159.26% | $46.27M |
| QTIQt Imaging Holdings Inc | $3.09 | — | 19.0x | — | -2125.30% | $45.23M |
| MGXMetagenomi Therapeutics, Inc. | $1.19 |
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Company description provided by Yahoo Finance.
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.4x |
| — |
| -60.61% |
| $44.95M |
| FLNAFilana Therapeutics Inc | $0.93 | — | 0.7x | — | -55.78% | $44.88M |
| TVGNTevogen Inc. | $6.89 | — | — | — | — | $44.86M |